Health and Me

Riya Baibhawi

Novo Nordisk's Diabetes Drug Could Be Beneficial For Heart, Study Shows

<span>Novo Nordisk</span> on Saturday announced that its diabetes pill, <span>Rybelsus</span>, demonstrated cardiovascular benefits in a late-stage trial. The findings pave the way for the medication to become a new treatment option for people living with both diabetes and heart disease.

In the trial, Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an average follow-up period of four years. The study involved patients with Type 2 diabetes and established heart disease, some of whom also had chronic kidney disease. The Danish drugmaker presented these results at the American College of Cardiology’s Annual Scientific Session in Chicago.

Rybelsus, already approved for Type 2 diabetes, is the once-daily oral formulation of Novo Nordisk’s blockbuster weekly injection, <span>Ozempic</span>. Both drugs, along with the company’s weekly weight-loss injection <span>Wegovy</span>, contain semaglutide as their active ingredient.

According to Stephen Gough, Novo Nordisk’s global chief medical officer, the company has submitted applications in the U.S. and EU to expand Rybelsus’ approval to include reducing the risk of serious cardiovascular events. “We know not everybody wants an injection, whether it is painful or not, they want the option of an oral medication,” Gough told CNBC. “We provide that option, that you can have one or the other, depending on what the patients and the healthcare professional think is right in that joint discussion.”

In March 2024, Wegovy received U.S. approval for lowering the risk of major cardiovascular events in adults who are overweight or obese and have heart disease. The new data on Rybelsus suggests an additional option for patients hesitant about injections, offering a more convenient pill-based treatment.

The phase three trial included over 9,600 participants aged 50 and older, who received either Rybelsus or a placebo, in addition to standard therapies. Nearly half of the participants also received SGLT2 inhibitors—commonly used to lower blood sugar—at some point during the trial. By the end, 12% of those on Rybelsus and 13.8% of those on placebo experienced cardiovascular-related death, heart attack, or stroke, amounting to a 14% overall reduction in risk for the Rybelsus group.

The most significant reduction was seen in non-fatal heart attacks, which were reduced by 26%, followed by a 12% drop in non-fatal strokes and a 7% reduction in cardiovascular-related deaths. These findings align with previous trials of injectable GLP-1s like semaglutide, which mimic gut hormones to regulate blood sugar, reduce appetite, and curb inflammation.

While the study showed no major differences in kidney-related outcomes, Gough clarified that the trial primarily focused on heart health. Ozempic, however, is already approved for treating chronic kidney disease in diabetic patients.

Common side effects of Rybelsus were gastrointestinal issues such as nausea, diarrhea, and constipation—similar to those experienced with injectable semaglutide. These symptoms rarely led to patients discontinuing the drug.

Dr. Darren McGuire, the study’s lead author from UT Southwestern Medical Center, noted that despite needing to be taken on an empty stomach at least 30 minutes before eating, patients successfully adhered to Rybelsus and experienced cardiovascular benefits across all age, sex, and health condition subgroups.

Health Conditions A-Z

health

Ozempic

wegovy

Novo Nordisk

Diabetes Drug

Rybelsus

Study Finds Controlling Inflammation In Diabetics Could Treat Depression, With Approaches Differing

Gallbladder Attacks on Repeat? A Nutritionist’s 8 Survival Tips Learnt The Hard Way

Actress Eva Amurri Says Her Back Hurts Looking at Before Photo: How Breast Reduction Can Relieve Chronic Back, Neck and Shoulder Pain

Health News

Superfoods That Support Your Gut Health

Immune-Boosting Foods To Have During Rainy Season

Potato Based Dishes You For Week-Long Meal Prep

Weight Loss Dishes With Fruits You Should Try

Stress Vs. Anxiety: Difference Explained In 60 seconds

Can You Get Heatstroke In Monsoon?

You’re Not Lazy! Women Do Need More Sleep Than Men

How To Ditch Daytime Sleepiness In Office?

Common Mistakes People Make While Eating Flaxseeds

Toddlers In India Are Missing Development Milestones: Study

Yoga Poses You Should Do For Back Pain

Healthy Brunch Ideas For A Lazy Weekend Meal

Balancing Exercises You Should Do For Stability

How Much Can Food Affect Menstruation?

What Should Fitness Look Like For A 13-18 Year Old

Food For Diabetes: What Should A Diabetic Diet Contain

You Don’t Always Need Weights For Strength Training

Feel Sleepy After Lunches - Light And Healthy Office Lunches

Positive Thinking Practice – How Does It Help You?

MIND Diet – Is This A Healthy Diet Or Another Trend?

Yoga Prop Essentials To Improve Your Exercise Session

Should Potatoes Be The Part Of A Healthy Diet?

Best And Worst Foods To Lower Blood Pressure

Low-Impact Cardio Workouts You Should Try

10 Healthy Pasta Salad Dressing For Weight Loss

Breathing Exercise You Should Do To Relieve Stress

Headache vs. Migraine: Difference Explained In 60 Seconds

High Carb Foods That Are Actually Healthy

How Many Times Do You Need To Wash Your Face?

Hypothyroidism Diet – What To Eat And What You Should Avoid

Stretches To Relieve Leg Pain And Numbness After Sitting For Too Long

No-Cook Healthy Meals For Lazy Days At Home

Easy Breakfast Options To Try During Calorie Deficit

How To Stop Muscle Cramps Immediately

Why You Should Go For An Anti-Inflammatory Diet

Foods To Lower Cortisol Levels In Your Body

High-Fiber Dips You Can Make At Home For The Week

Weekend Warrior Exercises To Makeup For Stressful Week

Experiencing Headaches At Word? Natural Remedies To Try

Yoga Poses That Enhance Digestion

Novo Nordisk on Saturday announced that its diabetes pill, Rybelsus, demonstrated cardiovascular benefits in a late-stage trial. The findings pave the way for the medication to become a new treatment option for people living with both diabetes and heart disease.In the trial, Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an average follow-up period of four years. The study involved patients with Type 2 diabetes and established heart disease, some of whom also had chronic kidney disease. The Danish drugmaker presented these results at the American College of Cardiology’s Annual Scientific Session in Chicago.Rybelsus, already approved for Type 2 diabetes, is the once-daily oral formulation of Novo Nordisk’s blockbuster weekly injection, Ozempic. Both drugs, along with the company’s weekly weight-loss injection Wegovy, contain semaglutide as their active ingredient.According to Stephen Gough, Novo Nordisk’s global chief medical officer, the company has submitted applications in the U.S. and EU to expand Rybelsus’ approval to include reducing the risk of serious cardiovascular events. “We know not everybody wants an injection, whether it is painful or not, they want the option of an oral medication,” Gough told CNBC. “We provide that option, that you can have one or the other, depending on what the patients and the healthcare professional think is right in that joint discussion.”In March 2024, Wegovy received U.S. approval for lowering the risk of major cardiovascular events in adults who are overweight or obese and have heart disease. The new data on Rybelsus suggests an additional option for patients hesitant about injections, offering a more convenient pill-based treatment.The phase three trial included over 9,600 participants aged 50 and older, who received either Rybelsus or a placebo, in addition to standard therapies. Nearly half of the participants also received SGLT2 inhibitors—commonly used to lower blood sugar—at some point during the trial. By the end, 12% of those on Rybelsus and 13.8% of those on placebo experienced cardiovascular-related death, heart attack, or stroke, amounting to a 14% overall reduction in risk for the Rybelsus group.The most significant reduction was seen in non-fatal heart attacks, which were reduced by 26%, followed by a 12% drop in non-fatal strokes and a 7% reduction in cardiovascular-related deaths. These findings align with previous trials of injectable GLP-1s like semaglutide, which mimic gut hormones to regulate blood sugar, reduce appetite, and curb inflammation.While the study showed no major differences in kidney-related outcomes, Gough clarified that the trial primarily focused on heart health. Ozempic, however, is already approved for treating chronic kidney disease in diabetic patients.Common side effects of Rybelsus were gastrointestinal issues such as nausea, diarrhea, and constipation—similar to those experienced with injectable semaglutide. These symptoms rarely led to patients discontinuing the drug.Dr. Darren McGuire, the study’s lead author from UT Southwestern Medical Center, noted that despite needing to be taken on an empty stomach at least 30 minutes before eating, patients successfully adhered to Rybelsus and experienced cardiovascular benefits across all age, sex, and health condition subgroups.

novo nordisk's diabetes drug could be beneficial for heart, study shows

Supriya Ramesh

Credis: Canva

FDA Approves First Neuroimmune Modulation Device for Rheumatoid Arthritis

fda approves first neuroimmune modulation device for rheumatoid arthritis

Health & Wellness

Can Obesity Cause Cancer? Study Finds A Link Between This Common Cause Of Obesity In Our Diet And Increased Risk Of Cancer

can obesity cause cancer? study finds a link between this common cause of obesity in our diet and increased risk of cancer

How Fast Is Your Heart Aging? A New Tool Can Find Your Cardiovascular Biological Age

how fast is your heart aging? a new tool can find your cardiovascular biological age

What Eating Sugar Does to Your Teeth and Why Oral Health Could Shape Your Whole Body’s Wellbeing

what eating sugar does to your teeth and why oral health could shape your whole body’s wellbeing

Living with <span>diabetes</span> is already challenging enough, and it comes with <span>depression</span>. Scientists say people with diabetes are up to twice as likely to experience depressive symptoms compared to those without it. But a new study suggests that controlling <span>inflammation</span> in the body could help treat depression in diabetics. However, the best approach depends on the type of diabetes you have.

Type 1 and type 2 diabetes are not the same. The latter is mostly known for the body’s inability to manage blood sugar effectively. In type 1 diabetes, on the other hand, the immune system attacks the insulin-producing cells in the pancreas, leaving the body without its natural blood sugar control.

Researchers have long known that both types can affect <span>mental health</span>. But this new work, published in the journal Diabetologia, suggests that the kind of inflammation happening in your body could hold the key to finding the most effective <span>treatment</span> for depression. 

Diabetes and depression often form a harmful feedback loop. High blood sugar can trigger fatigue and brain fog, depression can lead to poor self-care, and the cycle rolls on. Add inflammation to the mix, a biological response that can affect brain chemistry, and it becomes even harder to break free from the spiral.

The researchers from the Research Institute of the Diabetes Academy Mergentheim (FIDAM) in Germany decided to explore exactly how inflammation affects the success of depression treatments in people with diabetes. They measured 76 different inflammatory markers in the blood of 521 participants with type 1 or type 2 diabetes, all of whom were being monitored for depressive symptoms over a year.

<h3>Behavioural Therapy Works But Not the Same for Everyone</h3>

One of the main treatments tested was <span>cognitive behavioural therapy</span> (CBT), a structured form of psychotherapy that focuses on changing unhelpful thought patterns.

For people with type 2 diabetes and high inflammation levels, CBT worked wonders, reducing symptoms like joylessness and helping patients shift towards more positive thinking.

But for those with type 1 diabetes and similarly high inflammation levels, CBT didn’t have the same magic. Improvements were smaller, especially for symptoms like fatigue, trouble sleeping, or loss of appetite. This suggests that the underlying biology, in this case, the type of inflammation, plays a huge role in determining whether a therapy hits the mark.

The researchers believe it comes down to the nature of the inflammation. In type 2 diabetes, inflammation is largely metabolic, a consequence of the body’s inability to handle blood sugar properly. In type 1 diabetes, the inflammation is autoimmune; the immune system itself is attacking parts of the body.

These two processes likely influence the brain and mood in different ways, which might explain why CBT was a better fit for type 2 diabetics, while type 1 diabetics with high inflammation could benefit more from treatments aimed at reducing inflammation directly, such as anti-inflammatory drugs.

The data revealed an intriguing split. In people with type 2 diabetes, higher levels of 26 <span>biomarkers</span> were linked to bigger improvements in depression symptoms after CBT. In type 1 diabetes, higher levels of 13 biomarkers were actually linked to smaller improvements.

This is more than a curious statistic; it could be the basis for personalised mental health care in diabetes. Instead of trying the same approach for everyone, doctors might one day test inflammation markers first, then choose the right therapy based on each patient’s biological profile.

For diabetics, depression isn’t just an emotional burden; it can directly affect physical health. Low mood can make it harder to stick to a treatment plan, exercise, or eat well. Addressing both conditions at once could lead to better long-term health outcomes.

As study author Norbert Hermanns says, people with type 2 diabetes and high inflammation levels possibly respond particularly well to a change in depressive cognitions through cognitive behavioural therapy. People with type 1 diabetes and high inflammation levels, on the other hand, could benefit more from anti-inflammatory drug therapies.

The right combination of physical and mental health treatments could help patients feel better faster.

<h3>The Future of Tailored Treatments</h3>

The idea of personalised medicine is gaining traction in all areas of healthcare, and this research shows why. In the future, doctors could run a simple blood test, see which inflammatory markers are elevated, and then decide whether a patient might do best with therapy, medication, or both.

inflammation

diabetes

depression

cognitive behavioural therapy

inflammatory drugs

biomarkers

autoimmune disorder

metabolic condition

treatment

mental health

Living with diabetes is already challenging enough, and it comes with depression. Scientists say people with diabetes are up to twice as likely to experience depressive symptoms compared to those without it. But a new study suggests that controlling inflammation in the body could help treat depression in diabetics. However, the best approach depends on the type of diabetes you have.The Two TypesType 1 and type 2 diabetes are not the same. The latter is mostly known for the body’s inability to manage blood sugar effectively. In type 1 diabetes, on the other hand, the immune system attacks the insulin-producing cells in the pancreas, leaving the body without its natural blood sugar control.Researchers have long known that both types can affect mental health. But this new work, published in the journal Diabetologia, suggests that the kind of inflammation happening in your body could hold the key to finding the most effective treatment for depression. Diabetes and depression often form a harmful feedback loop. High blood sugar can trigger fatigue and brain fog, depression can lead to poor self-care, and the cycle rolls on. Add inflammation to the mix, a biological response that can affect brain chemistry, and it becomes even harder to break free from the spiral.The Study The researchers from the Research Institute of the Diabetes Academy Mergentheim (FIDAM) in Germany decided to explore exactly how inflammation affects the success of depression treatments in people with diabetes. They measured 76 different inflammatory markers in the blood of 521 participants with type 1 or type 2 diabetes, all of whom were being monitored for depressive symptoms over a year.Behavioural Therapy Works But Not the Same for EveryoneOne of the main treatments tested was cognitive behavioural therapy (CBT), a structured form of psychotherapy that focuses on changing unhelpful thought patterns.For people with type 2 diabetes and high inflammation levels, CBT worked wonders, reducing symptoms like joylessness and helping patients shift towards more positive thinking.But for those with type 1 diabetes and similarly high inflammation levels, CBT didn’t have the same magic. Improvements were smaller, especially for symptoms like fatigue, trouble sleeping, or loss of appetite. This suggests that the underlying biology, in this case, the type of inflammation, plays a huge role in determining whether a therapy hits the mark.Why the Difference?The researchers believe it comes down to the nature of the inflammation. In type 2 diabetes, inflammation is largely metabolic, a consequence of the body’s inability to handle blood sugar properly. In type 1 diabetes, the inflammation is autoimmune; the immune system itself is attacking parts of the body.These two processes likely influence the brain and mood in different ways, which might explain why CBT was a better fit for type 2 diabetics, while type 1 diabetics with high inflammation could benefit more from treatments aimed at reducing inflammation directly, such as anti-inflammatory drugs.The Numbers Don’t LieThe data revealed an intriguing split. In people with type 2 diabetes, higher levels of 26 biomarkers were linked to bigger improvements in depression symptoms after CBT. In type 1 diabetes, higher levels of 13 biomarkers were actually linked to smaller improvements.This is more than a curious statistic; it could be the basis for personalised mental health care in diabetes. Instead of trying the same approach for everyone, doctors might one day test inflammation markers first, then choose the right therapy based on each patient’s biological profile.Why This MattersFor diabetics, depression isn’t just an emotional burden; it can directly affect physical health. Low mood can make it harder to stick to a treatment plan, exercise, or eat well. Addressing both conditions at once could lead to better long-term health outcomes.As study author Norbert Hermanns says, people with type 2 diabetes and high inflammation levels possibly respond particularly well to a change in depressive cognitions through cognitive behavioural therapy. People with type 1 diabetes and high inflammation levels, on the other hand, could benefit more from anti-inflammatory drug therapies.The right combination of physical and mental health treatments could help patients feel better faster.The Future of Tailored TreatmentsThe idea of personalised medicine is gaining traction in all areas of healthcare, and this research shows why. In the future, doctors could run a simple blood test, see which inflammatory markers are elevated, and then decide whether a patient might do best with therapy, medication, or both.

study finds controlling inflammation in diabetics could treat depression, with approaches differing

Aarushi Bhadury

Delhi Malaria Cases Increase, Highest Number Of Cases In 5 Years

Surge in ‘Stratus’ Covid-19 Cases in the US: CDC Report Says, What Are The Symptoms?

covid-19 summer surge in the us gets worse, cdc says west has the highest levels - are there new symptoms?

US Faces Nationwide STD Epidemic As Cases Surge Past 2.3 Million

us faces nationwide std epidemic as cases surge past 2.3 million

Explained: An Overview Of How Vaccine Policies Have Changed Under RFK Jr

explained: an overview of how vaccine policies have changed under rfk jr

After a day of heavy rain, Delhi is facing a serious health concern, a sharp rise in mosquito-borne illnesses. With waterlogged streets and poor drainage, <span>malaria</span> cases have hit a five-year high. According to the latest data, 135 cases were reported from January 1 to August 2, marking the highest number for this period in the last five years. 

<h2>What Areas In Delhi Are Seeing A Rise In Malaria Cases? </h2>

The city of Delhi is seeing a worrying increase in malaria cases. The West Zone of the city has been hit the hardest, with 30 confirmed cases. This recent data comes from different parts of Delhi, including areas managed by the New Delhi Municipal Council, <span>Delhi Cantt</span>, and Indian Railways. 

As of August 2nd, the number of malaria cases has been growing year after year, with this year’s total of 135 cases being the highest in the last five years for the same period. City officials say this is happening because of a "perfect environment for mosquitoes to breed." They have found that common places where mosquitoes are growing include water-filled coolers, flower pots, drums, and even old tires left on rooftops. 

<h2>Vector-Borne Diseases Also a Concern </h2>

Malaria is a serious, life-threatening disease common in tropical countries. It is spread to people through the bite of certain types of infected mosquitoes. The good news is that malaria is both preventable and curable. Unfortunately, malaria isn't the only mosquito-related problem. Two other diseases carried by mosquitoes are also on the rise: 

<strong>Chikungunya:</strong> So far this year, there have been 20 cases. The West and Central Zones of the city have each reported five cases. This is a noticeable jump from previous years, with a total of 267 cases reported in all of 2024. 

<strong>Dengue: </strong>The city has also seen 291 cases of dengue. The Central Zone has the most cases, with 39. Last year, 11 people sadly died from this disease. 

To fight this problem, health officials have been inspecting homes. They've found that mosquitoes are breeding in over 100,000 houses and have sent out around 76,000 legal notices to residents to clean up these spots. 

<h2>Why Should Malaria Be A Cause Of Concern For People? </h2>

According to IJID Regions journal, Malaria remains a significant health challenge in India, with about 1.3 billion people at risk and over 180,000 cases reported in 2022. The Indian government has been working hard to control and reduce the number of malaria cases. This report looked closely at these efforts and found that several programs have been successful. 

The <span>Urban Malaria Scheme</span>, which focuses on 131 cities, and the Intensified Malaria Control Project, which targets seven high-risk areas, have both been very effective. 

A newer plan, the National Framework for Malaria Elimination, has also helped reduce cases in states like Odisha, which was once a major hotspot for the disease. 

If you think you have malaria, it's essential to get tested right away with a simple blood test. Early treatment can stop a mild case from becoming severe. Doctors will prescribe specific medicines based on the type of malaria and the person's age and health. 

A major challenge in fighting malaria today is that the parasites and mosquitoes are becoming resistant to our medicines and insecticides. Scientists are working on new solutions, like new-generation mosquito nets and updated treatment plans, to combat this resistance and keep the disease under control. 

You can protect yourself from malaria by avoiding mosquito bites and taking special medication, especially if you are traveling to an area where malaria is common. To avoid mosquito bites: 

<ul><li>Use mosquito nets when you sleep</li><li>Wear protective clothing like long sleeves and pants.</li><li>Use mosquito repellent on your skin.</li><li>Install screens on your windows and doors.</li></ul>

malaria

delhi cantt

urban malaria scheme

Delhi Malaria Cases Increase

Delhi Malaria

Malaria Cases and monsoon

Rise In Malaria Number

After a day of heavy rain, Delhi is facing a serious health concern, a sharp rise in mosquito-borne illnesses. With waterlogged streets and poor drainage, malaria cases have hit a five-year high. According to the latest data, 135 cases were reported from January 1 to August 2, marking the highest number for this period in the last five years. What Areas In Delhi Are Seeing A Rise In Malaria Cases? The city of Delhi is seeing a worrying increase in malaria cases. The West Zone of the city has been hit the hardest, with 30 confirmed cases. This recent data comes from different parts of Delhi, including areas managed by the New Delhi Municipal Council, Delhi Cantt, and Indian Railways. As of August 2nd, the number of malaria cases has been growing year after year, with this year’s total of 135 cases being the highest in the last five years for the same period. City officials say this is happening because of a "perfect environment for mosquitoes to breed." They have found that common places where mosquitoes are growing include water-filled coolers, flower pots, drums, and even old tires left on rooftops. Vector-Borne Diseases Also a Concern Malaria is a serious, life-threatening disease common in tropical countries. It is spread to people through the bite of certain types of infected mosquitoes. The good news is that malaria is both preventable and curable. Unfortunately, malaria isn't the only mosquito-related problem. Two other diseases carried by mosquitoes are also on the rise: Chikungunya: So far this year, there have been 20 cases. The West and Central Zones of the city have each reported five cases. This is a noticeable jump from previous years, with a total of 267 cases reported in all of 2024. Dengue: The city has also seen 291 cases of dengue. The Central Zone has the most cases, with 39. Last year, 11 people sadly died from this disease. To fight this problem, health officials have been inspecting homes. They've found that mosquitoes are breeding in over 100,000 houses and have sent out around 76,000 legal notices to residents to clean up these spots. Why Should Malaria Be A Cause Of Concern For People? According to IJID Regions journal, Malaria remains a significant health challenge in India, with about 1.3 billion people at risk and over 180,000 cases reported in 2022. The Indian government has been working hard to control and reduce the number of malaria cases. This report looked closely at these efforts and found that several programs have been successful. The Urban Malaria Scheme, which focuses on 131 cities, and the Intensified Malaria Control Project, which targets seven high-risk areas, have both been very effective. A newer plan, the National Framework for Malaria Elimination, has also helped reduce cases in states like Odisha, which was once a major hotspot for the disease. How to Stay Safe from Malaria?If you think you have malaria, it's essential to get tested right away with a simple blood test. Early treatment can stop a mild case from becoming severe. Doctors will prescribe specific medicines based on the type of malaria and the person's age and health. A major challenge in fighting malaria today is that the parasites and mosquitoes are becoming resistant to our medicines and insecticides. Scientists are working on new solutions, like new-generation mosquito nets and updated treatment plans, to combat this resistance and keep the disease under control. You can protect yourself from malaria by avoiding mosquito bites and taking special medication, especially if you are traveling to an area where malaria is common. To avoid mosquito bites: Use mosquito nets when you sleepWear protective clothing like long sleeves and pants.Use mosquito repellent on your skin.Install screens on your windows and doors.

delhi malaria cases increase, highest number of cases in 5 years

COVID-19 Summer Surge In The Us Gets Worse, CDC Says West Has The Highest Levels - Are There New Symptoms?

US Schools Reopen: Here Is Your Guide To The Lifesaving Vaccines Every Child Should Have

us schools reopen: here is your guide to the lifesaving vaccines every child should have

The spread of COVID-19 is picking up speed this summer in the US. The key indicator of the virus shows that it's becoming more active, according to the latest data released by the Centers for Disease Control and Prevention (CDC). 

<h2>How Are The Levels Of COVID Being Measure? </h2>

The CDC has a great way of tracking viruses: by checking our wastewater. This is a very helpful tool because it can find signs of the virus spreading in a community even before people start feeling sick and go to the doctor. In a recent update, the CDC reported that the amount of COVID-19 found in wastewater across the country has gone up from a "low" level to a "moderate" level. 

This is a clear sign that the virus is becoming more common. The data also shows that the highest levels of the virus are currently in the Western part of the country. States like Alaska, California, Colorado, Nevada, and Utah are seeing the most activity. If you live in one of these areas, it's a good idea to be a little more careful, as the risk of getting infected is higher. 

Other data also confirms the increase in cases. As of Tuesday, the CDC estimates that infections are growing or likely growing in 45 states, a jump from 40 states the previous week. 

This late-summer rise is being driven in part by a new variant, XFG, or "<span>Stratus</span>," which is now the third-most common strain in the U.S. The variant was first found in Southeast Asia in January but didn't become a major presence in the U.S. until May. By late June, it was estimated to account for up to 14% of cases. 

<h2>What Is The Current Strain Of COVID Affecting The US? </h2>

The World Health Organization explains that a new COVID-19 variant, called XFG, is now being watched closely by health experts around the world. Gavi vaccine alliance explains that Two new variants are now getting attention from scientists: NB.1.8.1, nicknamed "Nimbus," and XFG, nicknamed "Stratus." 

Both variants are spreading very quickly. Since early 2025, they have spread across the globe. For example, XFG accounted for 25% of cases in Europe by late May, while NB.1.8.1 was at 11% in late April. 

However, despite their rapid spread, experts say there's no evidence that these variants cause more severe illness, hospitalizations, or deaths than other versions of the virus. 

XFG ("Stratus") is good at evading our immune system. It has specific mutations that help it dodge antibodies, making it harder for our bodies to fight off. However, it doesn't seem to be as good as NB.1.8.1 at infecting cells. 

<h2>Is Stratus COVID Strain Dangerous? </h2>

WHO explains that the number of XFG cases is rising around the world. It’s now found in 38 countries and is growing quickly, especially in parts of Asia, the Americas, and Europe. In some countries, like India, XFG has become the main variant. 

Despite this increase, experts believe the global risk of XFG is low. Early data suggests that this variant doesn’t cause more severe illness or lead to more deaths than other variants currently spreading. 

<h2>Do Vaccines Work for Stratus COVID Strain? </h2>

Experts believe that the current COVID-19 vaccines will still be effective against XFG. They are expected to protect people from getting seriously sick or needing to go to the hospital. 

While some countries in Southeast Asia have seen more cases and hospitalizations at the same time as XFG became more common, it's not clear if the variant itself is causing this. It's too early to say for sure how big this new wave of cases will get. 

<h2>What Are The Key Symptoms of Stratus? </h2>

Doctors have reported that a standout symptom some patients with XFG have experienced a "hoarseness" feeling of scratchiness in their throat. Other symptoms include common issues like fever, chills, dry cough, fatigue, muscle ache, nasal congestion, nausea, vomiting or diarrhea.

Although XFG is spreading quickly, it doesn't appear to be more dangerous. The WHO continues to monitor them closely to see if that changes. 

COVID 19 Summer Surge

COVID 19 Summer In US

US and Covid 19 cases

new covid 19 strain

stratus

New symptoms of COVID 19

The spread of COVID-19 is picking up speed this summer in the US. The key indicator of the virus shows that it's becoming more active, according to the latest data released by the Centers for Disease Control and Prevention (CDC). How Are The Levels Of COVID Being Measure? The CDC has a great way of tracking viruses: by checking our wastewater. This is a very helpful tool because it can find signs of the virus spreading in a community even before people start feeling sick and go to the doctor. In a recent update, the CDC reported that the amount of COVID-19 found in wastewater across the country has gone up from a "low" level to a "moderate" level. This is a clear sign that the virus is becoming more common. The data also shows that the highest levels of the virus are currently in the Western part of the country. States like Alaska, California, Colorado, Nevada, and Utah are seeing the most activity. If you live in one of these areas, it's a good idea to be a little more careful, as the risk of getting infected is higher. Other data also confirms the increase in cases. As of Tuesday, the CDC estimates that infections are growing or likely growing in 45 states, a jump from 40 states the previous week. This late-summer rise is being driven in part by a new variant, XFG, or "Stratus," which is now the third-most common strain in the U.S. The variant was first found in Southeast Asia in January but didn't become a major presence in the U.S. until May. By late June, it was estimated to account for up to 14% of cases. What Is The Current Strain Of COVID Affecting The US? The World Health Organization explains that a new COVID-19 variant, called XFG, is now being watched closely by health experts around the world. Gavi vaccine alliance explains that Two new variants are now getting attention from scientists: NB.1.8.1, nicknamed "Nimbus," and XFG, nicknamed "Stratus." Both variants are spreading very quickly. Since early 2025, they have spread across the globe. For example, XFG accounted for 25% of cases in Europe by late May, while NB.1.8.1 was at 11% in late April. However, despite their rapid spread, experts say there's no evidence that these variants cause more severe illness, hospitalizations, or deaths than other versions of the virus. XFG ("Stratus") is good at evading our immune system. It has specific mutations that help it dodge antibodies, making it harder for our bodies to fight off. However, it doesn't seem to be as good as NB.1.8.1 at infecting cells. Is Stratus COVID Strain Dangerous? WHO explains that the number of XFG cases is rising around the world. It’s now found in 38 countries and is growing quickly, especially in parts of Asia, the Americas, and Europe. In some countries, like India, XFG has become the main variant. Despite this increase, experts believe the global risk of XFG is low. Early data suggests that this variant doesn’t cause more severe illness or lead to more deaths than other variants currently spreading. Do Vaccines Work for Stratus COVID Strain? Experts believe that the current COVID-19 vaccines will still be effective against XFG. They are expected to protect people from getting seriously sick or needing to go to the hospital. While some countries in Southeast Asia have seen more cases and hospitalizations at the same time as XFG became more common, it's not clear if the variant itself is causing this. It's too early to say for sure how big this new wave of cases will get. What Are The Key Symptoms of Stratus? Doctors have reported that a standout symptom some patients with XFG have experienced a "hoarseness" feeling of scratchiness in their throat. Other symptoms include common issues like fever, chills, dry cough, fatigue, muscle ache, nasal congestion, nausea, vomiting or diarrhea.Although XFG is spreading quickly, it doesn't appear to be more dangerous. The WHO continues to monitor them closely to see if that changes. 

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Novo Nordisk's Diabetes Drug Could Be Beneficial For Heart, Study Shows

Quick Stories

Study Finds Controlling Inflammation In Diabetics Could Treat Depression, With Approaches Differing

Delhi Malaria Cases Increase, Highest Number Of Cases In 5 Years

Surge in ‘Stratus’ Covid-19 Cases in the US: CDC Report Says, What Are The Symptoms?

Health Conditions A-Z

Study Finds Controlling Inflammation In Diabetics Could Treat Depression, With Approaches Differing

Gallbladder Attacks on Repeat? A Nutritionist’s 8 Survival Tips Learnt The Hard Way

Actress Eva Amurri Says Her Back Hurts Looking at Before Photo: How Breast Reduction Can Relieve Chronic Back, Neck and Shoulder Pain